No connection

Search Results

ABBV vs HTFL

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
HTFL
Heartflow, Inc.
BEARISH
Price
$26.95
Market Cap
$2.31B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
HTFL
--
Forward P/E
ABBV
15.42
HTFL
-89.77
P/B Ratio
ABBV
-146.66
HTFL
7.65
P/S Ratio
ABBV
6.5
HTFL
13.13
EV/EBITDA
ABBV
15.27
HTFL
-34.43

Profitability

Gross Margin
ABBV
71.46%
HTFL
76.8%
Operating Margin
ABBV
35.5%
HTFL
-36.13%
Profit Margin
ABBV
4.0%
HTFL
-66.35%
ROE
ABBV
137.96%
HTFL
-111.37%
ROA
ABBV
9.59%
HTFL
-16.75%

Growth

Revenue Growth
ABBV
9.1%
HTFL
40.5%
Earnings Growth
ABBV
-88.7%
HTFL
--

Financial Health

Debt/Equity
ABBV
--
HTFL
0.07
Current Ratio
ABBV
0.72
HTFL
5.2
Quick Ratio
ABBV
0.47
HTFL
4.87

Dividends

Dividend Yield
ABBV
3.05%
HTFL
--
Payout Ratio
ABBV
490.15%
HTFL
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
HTFL BEARISH

HTFL exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational inefficiency. While the company maintains a strong liquidity position (Current Ratio 5.20) and impressive revenue growth of 40.5%, these are offset by deep negative profit margins (-66.35%) and a high Price/Sales multiple of 13.13. The combination of heavy insider selling ($62.54M) and consistent earnings misses suggests a significant disconnect between analyst optimism and internal sentiment.

Strengths
Strong YoY revenue growth of 40.50%
High gross margins (76.80%) indicating a scalable product
Very low debt-to-equity ratio (0.07)
Risks
Critical financial health (Piotroski F-Score 1/9)
Severe profitability issues with -66.35% profit margins
Aggressive valuation (P/S 13.13) relative to earnings performance

Compare Another Pair

ABBV vs HTFL: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Heartflow, Inc. (HTFL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile